stockportfolio.pro
Bausch + Lomb Corporation (BLCO)
Healthcare · Medical Instruments & Supplies · NYSE
Bausch + Lomb Corporation revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $3.41B | $3.77B | $3.77B | $4.15B | $4.79B | $5.10B |
| Gross profit | — | — | $2.25B | $2.50B | $2.92B | $3.05B |
| Net income | $-18.00M | $182.00M | $6.00M | $-260.00M | $-317.00M | $-360.00M |
| Net margin | -0.5% | 4.8% | 0.2% | -6.3% | -6.6% | -7.1% |
Source: Bausch + Lomb Corporation SEC filings (10-K).
Explore 6 years of Bausch + Lomb Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BLCO in your portfolio →
Bausch + Lomb Corporation financial history by metric
About Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Bausch + Lomb Corporation — frequently asked questions
What is Bausch + Lomb Corporation's revenue?
Bausch + Lomb Corporation (BLCO) reported revenue of $5.10B for fiscal year 2025, up 6.5% from the prior year, according to its SEC filings.
Is Bausch + Lomb Corporation profitable?
No — BLCO reported a net loss of $-360.00M in fiscal 2025.
What is BLCO's P/E ratio?
Bausch + Lomb Corporation trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Bausch + Lomb Corporation growing?
BLCO's revenue grew at roughly 8.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Bausch + Lomb Corporation have?
As of fiscal year 2025, BLCO carried roughly $5.08B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Bausch + Lomb Corporation's gross margin?
BLCO's gross margin was 59.8% in fiscal 2025 — gross profit of $3.05B on revenue of $5.10B.
What is Bausch + Lomb Corporation's market cap?
Bausch + Lomb Corporation (BLCO) has a market capitalization of about $5.39B, based on the latest data in our nightly-refreshed cache.
When does Bausch + Lomb Corporation's fiscal year end?
BLCO's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Bausch + Lomb Corporation's official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.